Overview
NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.
Last reviewed: 20 April 2022
Next review: We will review this decision if the company decides to make a submission.